Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
Therapy Name | VERU-111 |
Synonyms | |
Therapy Description |
VERU-111 (bisindole) inhibits tubulin polymerization which may lead to anti-tumor activities (J Clin Oncol 39, no. 6_suppl (February 20, 2021) 131-131). |
Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
---|---|---|---|---|
VERU-111 | bisindole|Sabizabulin | Antimicrotubule Agent 14 | VERU-111 (bisindole) inhibits tubulin polymerization which may lead to anti-tumor activities (J Clin Oncol 39, no. 6_suppl (February 20, 2021) 131-131). |
Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
---|
Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
---|---|---|---|---|---|---|
NCT04844749 | Phase III | Abiraterone Enzalutamide VERU-111 | Efficacy Evaluation of VERU-111 for mCRPC in Patients Who Have Failed at Least One Androgen Receptor Targeting Agent (VERU-111) | Terminated | USA | 0 |
NCT05079360 | Phase II | Everolimus + Exemestane Exemestane VERU-111 | Efficacy Evaluation of Sabizabulin Monotherapy Versus Active Control for Treatment of ER+HER2- Metastatic Breast Cancer | Withdrawn | USA | 0 |